Innoviva, Inc. Net Income 2010-2024 | INVA
Innoviva, Inc. net income from 2010 to 2024. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
Innoviva, Inc. Annual Net Income
(Millions of US $) |
| 2023 |
$180 |
| 2022 |
$214 |
| 2021 |
$266 |
| 2020 |
$224 |
| 2019 |
$157 |
| 2018 |
$395 |
| 2017 |
$134 |
| 2016 |
$60 |
| 2015 |
$-19 |
| 2014 |
$-168 |
| 2013 |
$-171 |
| 2012 |
$-19 |
| 2011 |
$-115 |
| 2010 |
$-84 |
| 2009 |
$-85 |
Innoviva, Inc. Quarterly Net Income
(Millions of US $) |
| 2024-09-30 |
$1 |
| 2024-06-30 |
$-35 |
| 2024-03-31 |
$37 |
| 2023-12-31 |
$62 |
| 2023-09-30 |
$82 |
| 2023-06-30 |
$1 |
| 2023-03-31 |
$35 |
| 2022-12-31 |
$-68 |
| 2022-09-30 |
$266 |
| 2022-06-30 |
$1 |
| 2022-03-31 |
$16 |
| 2021-12-31 |
$10 |
| 2021-09-30 |
$72 |
| 2021-06-30 |
$89 |
| 2021-03-31 |
$94 |
| 2020-12-31 |
$54 |
| 2020-09-30 |
$28 |
| 2020-06-30 |
$77 |
| 2020-03-31 |
$65 |
| 2019-12-31 |
$46 |
| 2019-09-30 |
$40 |
| 2019-06-30 |
$38 |
| 2019-03-31 |
$34 |
| 2018-12-31 |
$264 |
| 2018-09-30 |
$47 |
| 2018-06-30 |
$55 |
| 2018-03-31 |
$30 |
| 2017-12-31 |
$58 |
| 2017-09-30 |
$24 |
| 2017-06-30 |
$35 |
| 2017-03-31 |
$17 |
| 2016-12-31 |
$25 |
| 2016-09-30 |
$15 |
| 2016-06-30 |
$15 |
| 2016-03-31 |
$4 |
| 2015-12-31 |
$4 |
| 2015-09-30 |
$-5 |
| 2015-06-30 |
$-8 |
| 2015-03-31 |
$-11 |
| 2014-12-31 |
$-16 |
| 2014-09-30 |
$-21 |
| 2014-06-30 |
$-64 |
| 2014-03-31 |
$-68 |
| 2013-12-31 |
$-50 |
| 2013-09-30 |
$-47 |
| 2013-06-30 |
$-36 |
| 2013-03-31 |
$-37 |
| 2012-12-31 |
$-31 |
| 2012-09-30 |
$-35 |
| 2012-06-30 |
$-37 |
| 2012-03-31 |
$85 |
| 2011-12-31 |
$-37 |
| 2011-09-30 |
$-31 |
| 2011-06-30 |
$-25 |
| 2011-03-31 |
$-23 |
| 2010-12-31 |
$-19 |
| 2010-09-30 |
$-21 |
| 2010-06-30 |
$-21 |
| 2010-03-31 |
$-23 |
| 2009-12-31 |
$-22 |
| 2009-09-30 |
$-22 |
| 2009-06-30 |
$-22 |
| 2009-03-31 |
$-19 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharma |
$1.132B |
$0.310B |
|
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.
|
